Shionogi Advances Pompe Disease Treatment with Phase 2 Trial Launch
Event summary
- Shionogi enrolled the first patients in the global Phase 2 Esprit trial for S-606001, an investigational oral substrate reduction therapy (SRT) for late-onset Pompe disease (LOPD).
- The 52-week, multicenter, randomized, placebo-controlled study will evaluate S-606001 in combination with standard enzyme replacement therapy (ERT) across the U.S., EU, and UK.
- S-606001 targets glycogen synthase (GYS1) to limit glycogen buildup, potentially complementing ERT’s mechanism of increasing glycogen breakdown.
- Shionogi acquired S-606001 from Maze Therapeutics in 2024, with the drug receiving FDA rare pediatric disease and orphan drug designations.
The big picture
Shionogi’s Phase 2 trial launch for S-606001 reflects the growing focus on substrate reduction therapies as complementary treatments for LOPD, where ERT efficacy can diminish over time. The company’s acquisition of S-606001 aligns with its strategy to expand into rare diseases, following its 2025 acquisition of ALS treatment rights from Tanabe Pharma. Success in this trial could position Shionogi as a key player in LOPD management, addressing a significant unmet need in neuromuscular disorders.
What we're watching
- Clinical Efficacy
- Whether S-606001 can demonstrate meaningful efficacy as an add-on therapy to ERT in slowing LOPD progression.
- Regulatory Pathway
- The pace at which Shionogi advances S-606001 through Phase 2 and potential FDA approval timelines.
- Competitive Positioning
- How Shionogi differentiates S-606001 in the LOPD treatment landscape amid existing ERT therapies.
Related topics